A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Conditions
Advanced Solid Tumor · Advanced Breast Cancer · Advanced Ovarian Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Providence St. Jude Medical Center, Fullerton, California, United States
Marin Cancer Care, Greenbrae, California, United States
Moores Cancer Center, La Jolla, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Local Institution - 0008, Aurora, Colorado, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Contact: Study coordinator (Faisal Fa'ak)Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Northwell Health-Cancer Institute, New Hyde Park, New York, United States
Contact: Study coordinator (Geraldine O'Sullivan Coyne)Local Institution - 0011, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
START Dallas Fort Worth, Fort Worth, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
Odense Universitetshospital, Odense, Region Syddanmark, Denmark
Copenhagen University Hospital, Copenhagen, Denmark
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Kansai Medical University Hospital, Hirakata, Osaka, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb